Summary of Conference Call on China Healthcare Services: Drug Chains Industry Overview - The conference call discusses the **pharmaceutical retail industry** in China, particularly focusing on **drug chains** and retail pharmacies [1][4]. Key Points and Arguments 1. **Policy Support**: - Nine departments, including the Ministry of Commerce, issued opinions to promote high-quality development in the pharmaceutical retail industry, supporting consolidation and restructuring of retail pharmacies [1][2]. - This policy is expected to benefit leading players with scale and digital competence, allowing them to expand market shares through organic growth and M&A [1]. 2. **Implementation Timeline**: - The transition from policy announcement to actual implementation typically takes about one year, which may delay adjustments in earnings forecasts for pharmacy companies [2]. 3. **Market Recovery Indicators**: - The retail pharmacy sector is showing signs of recovery, with the total number of pharmacies increasing by **0.1% month-on-month in November 2025** and **2.5% in December 2025**, ending a 15-month contraction [3][8]. - Same-store sales growth (SSSG) has been positive year-on-year since May 2025, indicating a rebound in consumer spending [3][10]. 4. **Future Growth Expectations**: - For 2026, a combination of favorable policies and improving fundamentals is expected to drive leading pharmacy chains to outperform the broader industry in revenue growth [4]. - Buy ratings are reiterated for **Yifeng**, **Dashenlin**, and **LBX**, with projected earnings growth rates of **11.3%**, **13.9%**, and **21.2%** respectively [4]. Company-Specific Insights 1. **Yifeng Pharmacy**: - Target price set at **Rmb 34** based on a two-stage DCF valuation with a WACC of **8.5%** [33]. - Key risks include competition from e-commerce and regulatory changes [34]. 2. **LBX Pharmacy**: - Target price set at **Rmb 21** with similar valuation methodology as Yifeng [35]. - Risks include lower-than-expected store expansion and margin pressures [36]. 3. **Dashenlin**: - Target price set at **Rmb 24**, also based on a two-stage DCF valuation [37]. - Risks include competition from e-commerce and challenges in expanding market share outside Guangdong province [38]. Additional Important Information - The report emphasizes the importance of monitoring the implementation of new policies and their impact on the market, as well as the potential for M&A activity in the sector [2][4]. - The data from Pharmcube indicates stable revenues in mass-market products, while premium TCM products and healthcare supplements are experiencing revenue declines [12]. This summary encapsulates the key insights and projections regarding the pharmaceutical retail industry in China, highlighting the potential for growth and the associated risks for leading pharmacy chains.